Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Authors' conclusion
The results of this SLR, together with one SLR on safety of DMARD and one on glucocorticoids, informed the taskforce of the 2022 update of the EULAR recommendations for pharmacological management of RA.
Study context
- Population
- Patients with rheumatoid arthritis (RA); trials of csDMARDs, bDMARDs (incl. biosimilars) and tsDMARDs, articles published since 2019 update to 14 January 202247 articles included
Methodological detailsMedline, EMBASE, Cochrane CENTRAL and Web of Science searched; 8969 search results, 169 articles reviewed in detail
- Medline, EMBASE, Cochrane CENTRAL and Web of Science searched; 8969 search results, 169 articles reviewed in detail
Main finding
As reported in the abstract
- Efficacy of csDMARDs + short-term GC in early RA confirmed and similar to bDMARD+methotrexate (MTX) combination therapy
- IL-6 pathway inhibition effective in trials on olokizumab and levilimab
- Janus kinase inhibitor (JAKi) efficacious in different patient populations
- After insufficient response to JAKi, patients could respond to TNFi treatment
- Tapering of DMARDs feasible for a proportion of patients, remaining in low disease activity or remission
Original publication
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. Published 11 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →